High demand causes mumps vaccine shortage in Japan; OncoQCR's breast cancer vax succeeds in nonhuman primates;

> Higher-than-expected demand for the mumps vaccine has caused a shortage in Japan, though the shortfall is expected to be alleviated between next week and the end of November. Story

> OncoQCR's breast cancer vaccine candidate, OQR200, induced high levels of antibodies and T-cell responses to HER2/neu cancer cells in a nonhuman primate study. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.